• 제목/요약/키워드: Gynecologic neoplasm

검색결과 17건 처리시간 0.027초

부인암 환자의 생존단계별 건강증진행위, 외상 후 성장 및 삶의 질 비교 (The Comparison of Health Promotion Behavior, Post Traumatic Growth and Quality of Life according to Stages of Survivorship in Patients with Female Genital Neoplasm)

  • 이은실;박정숙
    • 성인간호학회지
    • /
    • 제25권3호
    • /
    • pp.312-321
    • /
    • 2013
  • Purpose: The purpose of this study was to compare health promotion behavior, post-traumatic growth and quality of life according to the stages of survivorship in patients with female genital neoplasm. Methods: Data were collected from August 1st, 2011 to September 31st 2011 from 142 gynecologic cancer patients who completed treatment or were treated at an out-patient clinic. The instrument were HPLP developed by Walker, Sechrist & Pender, PTGI developed by Tedeschi & Calhoun, and Korean C-QOL. Results: Health promotion behavior scores were significantly higher in the acute survival stage than the extended survival stage. Post-traumatic growth score was higher in the acute survival stage than the extended survival stage. The quality of life scores were higher in the lasting survival stage than the extended survival stage. Conclusion: Gynecological cancer patients in the extended survival stage reported low scores of health promotion behavior, post-traumatic growth and quality of life. Intervention needed to be developed to improve health promotion behavior, post-traumatic growth and quality of life for patients with female genital neoplasm in the extended survival stage.

Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p

  • Wang, Changhong;Qi, Shan;Xie, Cheng;Li, Chunfu;Wang, Pu;Liu, Dongmei
    • Journal of Gynecologic Oncology
    • /
    • 제29권6호
    • /
    • pp.99.1-99.11
    • /
    • 2018
  • Objective: The present study is to evaluate the biological functions of long non-coding RNA (lncRNA), X-inactive specific transcript, X-inactive specific transcript (XIST) in human epithelial ovarian cancer (EOC). Methods: XIST was upregulated in EOC cell lines, CAOV3 and OVCAR3 cells by lentiviral transduction. The effects of XIST overexpression on cancer cell proliferation, invasion, chemosensitivity and in vivo tumor growth were investigated, respectively. Possible sponging interaction between XIST and human microRNA hsa-miR-214-3p was further evaluated. Furthermore, hsa-miR-214-3p was overexpressed in XIST-upregulated CAOV3 and OVCAR3 cells to evaluate its effect on XIST-mediated EOC regulation. Results: Lentivirus-mediated XIST upregulation had significant anticancer effects in CAOV3 and OVCAR3 cells by suppressing cancer cell proliferation, invasion, increasing cisplatin chemosensitivity and inhibiting in vivo tumor growth. Hsa-miR-214-3p was confirmed to directly bind XIST, and inversely downregulated in XIST-upregulated EOC cells. In EOC cells with XIST upregulation, secondary lentiviral transduction successfully upregulated hsa-miR-214-3p expression. Subsequently, hsa-miR-214-3p upregulation functionally reversed the anticancer effects of XIST-upregulation in EOC. Conclusion: Upregulation of lncRNA XIST may suppress EOC development, possibly through sponging effect to induce hsa-miR-214-3p downregulation

Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide

  • Kanno, Toshiyuki;Matsui, Hideo;Akizawa, Yoshika;Usui, Hirokazu;Shozu, Makio
    • Journal of Gynecologic Oncology
    • /
    • 제29권6호
    • /
    • pp.89.1-89.8
    • /
    • 2018
  • Objective: Highly effective chemotherapy for patients with low-risk gestational trophoblastic neoplasia (GTN) is associated with almost a 100% cure rate. However, 20%-30% of patients treated with chemotherapy need to change their regimens due to severe adverse events (SAEs) or drug resistance. We examined the treatment outcomes of second-line chemotherapy for patients with low-risk GTN. Methods: Between 1980 and 2015, 281 patients with low-risk GTN were treated. Of these 281 patients, 178 patients were primarily treated with 5-day intramuscular methotrexate (MTX; n=114) or 5-day drip infusion etoposide (ETP; n=64). We examined the remission rates, the drug change rates, and the outcomes of second-line chemotherapy. Results: The primary remission rates and drug resistant rates of 5-day ETP were significantly higher (p<0.001) and significantly lower (p=0.002) than those of 5-day MTX, respectively. Forty-seven patients (26.4%) required a change in their chemotherapy regimen due to the SAEs (n=16) and drug resistance (n=31), respectively. Of these 47 patients failed the first-line regimen, 39 patients (39/47, 82.9%) were re-treated with single-agent chemotherapy, and 35 patients (35/39, 89.7%) achieved remission. Four patients failed second-line, single-agent chemotherapy and eight patients (17.0%) who failed first-line regimens were treated with combined or multi-agent chemotherapy and achieved remission. Conclusions: Patients with low-risk GTN were usually treated with single-agent chemotherapy, while 20%-30% patients had to change their chemotherapy regimen due to SAEs or drug resistance. The second-line regimens of single-agent chemotherapy were effective; however, there were several patients who needed multiple agents and combined chemotherapy to achieve remission.

Performance of pre-treatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis

  • Han, Sangwon;Woo, Sungmin;Suh, Chong Hyun;Lee, Jong Jin
    • Journal of Gynecologic Oncology
    • /
    • 제29권6호
    • /
    • pp.98.1-98.13
    • /
    • 2018
  • Objective: We describe a systematic review and meta-analysis of the performance of ${18}F$-fluorodeoxyglucose ($^{18}F-FDG$) positron emission tomography/computed tomography (PET/CT) for detecting metastasis in ovarian cancer. Methods: MEDLINE and Embase were searched for diagnostic accuracy studies that used $^{18}F-FDG$ PET or PET/CT for pre-treatment staging, using surgical findings as the reference standard. Sensitivities and specificities were pooled and plotted in a hierarchic summary receiver operating characteristic plot. Potential causes of heterogeneity were explored through sensitivity analyses. Results: Eight studies with 594 patients were included. The overall pooled sensitivity and specificity for metastasis were 0.72 (95% confidence interval [CI]=0.61-0.81) and 0.93 (95% CI=0.85-0.97), respectively. There was considerable heterogeneity in sensitivity ($I^2=97.57%$) and specificity ($I^2=96.74%$). In sensitivity analyses, studies that used laparotomy as the reference standard showed significantly higher sensitivity and specificity (0.77; 95% CI=0.67-0.87 and 0.96; 95% CI=0.92-0.99, respectively) than those including diagnostic laparoscopy (0.62; 95% CI=0.46-0.77 and 0.84; 95% CI=0.69-0.99, respectively). Higher specificity was shown in studies that confirmed surgical findings by pathologic evaluation (0.95; 95% CI=0.90-0.99) than in a study without pathologic confirmation (0.69; 95% CI=0.24-1.00). Studies with a lower prevalence of the FDG-avid subtype showed higher specificity (0.97; 95% CI=0.94-1.00) than those with a greater prevalence (0.89; 95% CI=0.80-0.97). Conclusion: Pre-treatment $^{18}F-FDG$ PET/CT shows moderate sensitivity and high specificity for detecting metastasis in ovarian cancer. With its low false-positive rate, it can help select surgical approaches or alternative treatment options.

Endometrial Stromal Sarcoma Presented as an Incidental Lung Mass with Multiple Pulmonary Nodules

  • Kang, Dong Oh;Choi, Sue In;Oh, Jee Youn;Sim, Jae Kyeom;Choi, Jong Hyun;Choo, Ji Yung;Hwang, Jin Wook;Lee, Seung Heon;Lee, Ju-Han;Lee, Ki Yeol;Shin, Chol;Kim, Je Hyeong
    • Tuberculosis and Respiratory Diseases
    • /
    • 제76권3호
    • /
    • pp.131-135
    • /
    • 2014
  • Low-grade endometrial stromal sarcoma (ESS) is an uncommon gynecologic malignancy of mesodermal origin. Pulmonary metastasis of low-grade ESS can occur years and decades after the treatment of the primary disease. Low-grade ESS is frequently mistaken as benign uterine neoplasm like uterine leiomyoma, which can potentially lead to a misdiagnosis. We present a case of a 42-year-old woman with low-grade ESS, that initially presented as an incidental lung mass with multiple pulmonary nodules, seven years after an uterine myomectomy. A $6.9{\times}5.8cm-sized$ intrapelvic mass suspected of uterine origin was discovered while searching for potential extrathoracic primary origin. A pelviscopy and simultaneous thoracoscopic lung biopsy were conducted for pathologic diagnosis. Finally, the diagnosis was confirmed as low-grade ESS with lung metastasis based on the histopathologic examination with immunohistochemical stain, which was showed positive for CD10 and hormone receptor markers (estrogen and progesterone receptors) in both pelvic and lung specimens.

항암화학요법을 받는 부인암 환자의 삶의 질에 관한 연구 (Quality of Life in Gynecological Cancer Patients During Chemotherapy)

  • 이주영;최스미
    • 여성건강간호학회지
    • /
    • 제13권4호
    • /
    • pp.290-298
    • /
    • 2007
  • Purpose: This study was to measure the quality of life(QOL) and to identify the related factors in gynecological cancer patients during chemotherapy. Method: The subjects of this study were the patients who had undergone a hysterectomy and were admitted for chemotherapy at S university hospital between November 2006 and April 2007. Data was collected from 106 gynecological cancer patients with the use of a structured questionnaire which measured the QOL(FACT-G), body image, the presence of anxiety & depression, uncertainty, and family support. The data was analyzed by the SPSS win 12.0 program. Results: The mean FACT-total score was 62.1$({\pm}16.7)$ (range; 26-107). Positive correlations were found between QOL and body image(r= .67, p= .00), and QOL and family support(r= .32, p= .00), whereas there were negative correlations between QOL and anxiety(r= -.54, p= .00), QOL and depression(r= -.70, p= .00), and QOL and uncertainty(r= -.59, p= .00). Fifty seven pre cent of the variance in subjective overall QOL can be explained by depression, body image, and uncertainty(Adj $R^2$= .57, F=47.00, p= .00). Conclusion: Our patients had a relatively low QOL score. Factors significantly affecting quality of life were depression, body image and uncertainty. Nursing interventions, therefore, should be focused on improving QOL in gynecological cancer patients during chemotherapy, particularly so in patients with depression, uncertainty or poor body image.

  • PDF

항암화학요법을 받는 부인암 환자의 치료 부작용, 우울 및 수면의 질의 관계 (Relationships between Side Effects, Depression and Quality of Sleep in Gynecological Cancer Patients Undergoing Chemotherapy)

  • 김영화;이지현
    • 여성건강간호학회지
    • /
    • 제16권3호
    • /
    • pp.276-287
    • /
    • 2010
  • Purpose: This study was to identity the relationships between the side effects of depression and quality of sleep among gynecological cancer patients undergoing chemotherapy. Methods: The data was collected from 113 patients at two general hospitals within B metropolitan city. The instruments used to collect the data for the study was the 'Side Effect Scale' developed by Kwon, Young-eun; 'Depression scale' developed by Oh, Se-man, and the 'Quality of Sleep Scale' developed by Oh, Song & Kim. Results: Results showed that the mean of side effects was $39.75{\pm}9.99$, mean of depression was $9.63{\pm}3.93$ and mean of 'quality of sleep' was $36.99{\pm}6.66$. The quality of sleep variable showed statistically significant differences for the variables: age (F=3.203, p=.026), cancer insurance (t=-2.278, p=.025), and perceived physical condition (F=3.152, p=.047) respectively. The relationship between side effects and quality of sleep showed a low negative, but significant correlation (r=-.327, p<.001). The relationship between depression and quality of sleep also showed a low negative correlation (r=-.365, p<.001). Conclusion: This study shows that it is necessary to develop nursing intervention programs because it can successfully improve the quality of sleep of gynecological cancer patients undergoing chemotherapy.